What is the visibility into the $2 million capital shift to H2 for Surgical Solutions? Can you break down growth by ultrasonics and BGS, and discuss capital vs. handpiece growth in ultrasonics?

Rob Claypool explained that Surgical Solutions grew 5% sequentially despite a difficult Q2 comparison and a $2 million timing impact (nearly 400 basis points for the segment). He highlighted strong traction in ultrasonics with new accounts, users, capital placements, and accelerated disposables growth. For BGS, proactive actions were taken for profitable growth, which had a temporary impact but led to positive traction with new large account acquisitions. “that alone was nearly a 400 basis point impact for surgical, The surgical business grew 5% sequentially in the second quarter.”

Is the strategic review process a fresh development, or has it been ongoing in the background before this public announcement?

Rob Claypool reiterated that the announcement was made due to an unsolicited acquisition proposal and multiple expressions of interest. He stated that the company could not provide further details but emphasized BioVentus's strong business, progress, and potential, and the committee's commitment to maximizing shareholder value. “we made the announcement today, given the unsolicited acquisition proposal that we received, along with multiple expressions of interest.”

Can you provide more color on customer reception for PRP and PNS, particularly how PRP capital placements are driving sales?

Rob Claypool expressed encouragement for PRP, citing velocity of new customers, accelerated capital placements, and increased size and frequency of reorders. He noted the synergistic leverage of the HA commercial team for PRP. For PNS, he highlighted team expansion, accelerated new customers and trials, and high conversion rates to implants, with positive market feedback. He reiterated the expectation for both to contribute 200 basis points to growth this year. “HA is helping us win PRP, and PRP is now helping us win business.”

BVS

BioVentus (BVS) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

BioVentus Q2 FY26 — Strong Performance Across Business, Strategic Review Initiated

BioVentus delivered solid Q2 FY26 results, driven by strong performance in Pain Treatments and disciplined cost management, leading to increased earnings and significant debt reduction. The company also announced a strategic review process initiated by its Board of Directors to evaluate options, including a potential sale, to maximize shareholder value. Despite some segment-specific headwinds, management reaffirmed full-year guidance, expressing confidence in its growth drivers and operational execution.

Highlights

Total revenue grew 4% year-over-year to $153 million.
Pain Treatments revenue grew 12% year-over-year to $82 million, driven by Duralane volume gains.
Adjusted EBITDA increased over $1 million, with a 23% margin, expanding 20 basis points year-over-year.
Adjusted EPS increased 24% year-to-date compared to prior year.
Net leverage reduced to below 2x, with $24 million debt repaid in Q2, bringing year-to-date repayment to $46 million.

Concerns

Surgical Solutions revenue declined 5% year-over-year to $50 million, impacted by timing of capital placements and international orders ($2 million shift).
Restorative Therapies revenue declined 2% to $21 million due to a change in mix with fewer Medicare patients.
International revenue was lower by 1% (2% constant currency) to $19 million due to timing of distributor orders.
Adjusted gross margin decreased 90 basis points to 75% due to higher freight costs and product mix.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$600 million to $610 million high materiality	FY26	High
Full-year 2026 Adjusted EPS	$0.75 to $0.79 high materiality	FY26	High
Full-year 2026 Cash from Operations	$84 million and $89 million high materiality	FY26	High
Full-year 2026 Adjusted EBITDA Margin	at least 20% medium materiality	FY26	High
Net Leverage	below 1.5 times high materiality	Q4 · FY26	High
Second Half Revenue Growth	increase by over 300 basis points medium materiality	H2 FY26	High
Second Half Cash from Operations	approximately double medium materiality	H2 FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Global Pain Treatments Driven by strong growth in HA from volume gains with differentiated single injection Duralane therapy and favorable customer mix. Success reflects intense focus and strategic collaboration across salesforce, corporate accounts, and pricing teams. Duralane volume growth: double-digitHA franchise performance: above marketPRP and PNS contributions: positive	$82 million	12%	—	—
Surgical Solutions Impacted by challenging prior year comparison and timing of certain ultrasonics capital placements and international orders, shifting approximately $2 million of revenue into the second half. Deliberate portfolio actions were taken to prioritize higher margin profitable growth opportunities in BGS. Ultrasonics disposables performance: acceleratingBGS traction: significant with new large accounts and IDNs	$50 million	-5%	5%	—
Restorative Therapies Resulted from a change in mix, specifically with Medicare patients, in addition to a difficult comparison to the prior year. Growth is expected to resume based on current business opportunities.	$21 million	-2%	—	—
International Primarily due to the timing of distributor orders. Fundamental growth continues to be strong, and with increased strategic focus, talent additions, and improved commercial execution, strong double-digit growth is expected in the second half and for the full year. Constant currency growth: -2%	$19 million	-1%	—	—

Deals & partnerships

Unnamed parties Evaluation of strategic options, including a potential sale of the company or continued standalone execution.

The Board has formed a committee of independent directors, assisted by Evercore as financial advisor, to evaluate options following an unsolicited acquisition proposal and multiple expressions of interest.

Risks & headwinds

Challenging prior year comparison Q2 FY26

Impacted Surgical Solutions (-5% YoY) and Restorative Therapies (-2% YoY).

Timing of orders and capital placements Q2 FY26

Shifted approximately $2 million of revenue from Q2 to H2, impacting Surgical Solutions and International.

Mitigation:Expected to accelerate revenue in H2 FY26.

Product mix and higher freight costs Q2 FY26

Led to a 90 basis point decline in adjusted gross margin to 75%.

Change in customer mix Q2 FY26

Specifically with fewer Medicare patients, impacting Restorative Therapies revenue (-2% YoY).

Mitigation:Expected growth to resume based on current business opportunities.

Increased effective tax rate Q2 FY26 and full year

Increased compared to prior year.

What to watch in Q3 FY26

Surgical Solutions revenue acceleration

H2 FY26

Current -5% YoY in Q2, 5% sequential growth

Target Strong acceleration in H2, including $2M shift from Q2

Why it matters

Critical for overall revenue growth and achieving full-year guidance.

More importantly, we saw great traction in ultrasonics with our leading indicators from our investments, including new accounts, new users, capital placements, and accelerated sequential growth with disposables. So we're really looking forward to the second half of the year.

Find out whether BVS delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you elaborate on the drivers of HA growth (volume vs. price) and how BioVentus and its leading competitor are both gaining share in the single-injection market?

Rob Claypool stated that HA growth, particularly for Duralane, was led by double-digit volume growth. He attributed this to clinical differentiation, broad private payer coverage, and commercial strength, emphasizing that the company's progress in this space is primarily volume-driven.

“our progress and growth in this space is really driven by volume growth.”

asked by Chase Knickerbocker · answered by Robert Claypoole

2 min read 6 chapters

Detailed narrative

Strategic Review Initiated

BioVentus announced that its Board of Directors has formed a committee of independent directors to evaluate a range of strategic options, including a potential sale of the company or the continued execution of its standalone plan. This decision follows the receipt of multiple expressions of interest and an unsolicited acquisition proposal.

Evercore has been appointed as the financial advisor to assist the committee in maximizing shareholder value.

Durable Growth in Pain Treatments

The Pain Treatments business delivered strong double-digit growth in Q2 FY26, primarily driven by the HA franchise, led by Duralane. This market-leading single-injection therapy continues to outperform the market, fueled by strong commercial focus, clinical differentiation, and broad private payer coverage. The significant operating profit generated from this franchise is being strategically deployed to invest in other key growth drivers.

Investments in Key Growth Drivers Yielding Traction

BioVentus is increasing investments in platelet-rich plasma (PRP), peripheral nerve stimulation (PNS), ultrasonics, and international markets. These investments include expanding commercial teams, raising awareness, and enhancing physician training. Early indicators show positive traction, such as accelerating capital placements and disposable reorders for PRP, increased surgeon adoption and high conversion rates for PNS implants, and growing surgeon adoption and disposables growth for ultrasonics.

Enhanced Earnings Power and Operational Discipline

Despite accelerating investments in growth drivers, BioVentus demonstrated enhanced earnings power, delivering an adjusted EBITDA margin of 23% in Q2, a 20 basis point expansion year-over-year. The company expects to maintain a full-year adjusted EBITDA margin of at least 20%. This is achieved by leveraging durable revenue growth, stable gross margins, and disciplined cost management across the business.

Strengthening Balance Sheet and Capital Allocation

The company generated strong cash flow from operations, enabling an additional $24 million in debt repayment during Q2, bringing the year-to-date total to $46 million. This reduced net leverage to below 2x, with a target of below 1.5x by year-end. This deleveraging strategy aims to strengthen the financial position, drive further interest expense savings, and enhance future capital deployment optionality.

Segment-Specific Dynamics

Surgical Solutions revenue declined 5% year-over-year but grew 5% sequentially, impacted by a $2 million timing shift of capital placements and international orders. Restorative Therapies saw a 2% decline due to a shift in Medicare patient mix, though growth is expected to resume.

International revenue was down 1% (2% constant currency) due to distributor order timing, but strong double-digit growth is anticipated in the second half.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.